Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1

Interventions

fludarabine phosphate 4Rituximab 4Peripheral Blood Stem Cell Transplantation 3tislelizumab 2pegaspargase 2Whole-Body Irradiation 2Mycophenolic Acid 2Microarray Analysis 2Immunohistochemistry 2Ifosfamide 2Gene Expression Profiling 2Gemcitabine 2Everolimus 2Etoposide 2Cyclosporine 2Cyclophosphamide 2Carboplatin 2Bendamustine Hydrochloride 2veliparib 1relatlimab 1liposomal doxorubicin 1indolepropanol phosphate 1gemcitabine-oxaliplatin regimen 1etoposide phosphate 1ethanolamine oleate 1copanlisib 1aldesleukin 1WW Domain-Containing Oxidoreductase 1Vorinostat 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Extranodal NK-T-Cell × Commerce × Clear all
NCT00481871 2020-01-07

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Acrotech Biopharma Inc.

Phase 1/2 Completed
119 enrolled 13 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡